Stockscreener 앱 받기
10.82
23.23%
2.04
시간 외 거래:
10.20
-0.62
-5.73%
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
Kyverna (NASDAQ:KYTX) Reports Positive Phase 2 Data for CAR T Therapy in Stiff Person Syndrome - Kalkine Media
Kyverna Therapeutics Inc. (KYTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kyverna May Be On Track To Bring First CAR-T For Autoimmune Disease To Market - Citeline News & Insights
Stock Market Today, Dec. 15: U.S Stocks Ease as Investors Wait for Rate Clarity - The Motley Fool
Kyverna Therapeutics launches $100 million public stock offering By Investing.com - Investing.com Nigeria
Leerink raises Kyverna price target, says KYSA-8 study results transformative - TipRanks
Kyverna Therapeutics launches $100 million public stock offering - Investing.com India
Kyverna Therapeutics stock falls after $100M public offering announcement By Investing.com - Investing.com Nigeria
Kyverna Therapeutics announces proposed public offering of common stock - marketscreener.com
Kyverna Therapeutics stock falls after $100M public offering announcement - Investing.com India
Kyverna Therapeutics (NASDAQ: KYTX) launches $100M stock sale with $15M underwriters’ option - Stock Titan
Kyverna Therapeutics’ Promising KYSA-8 Study and Strategic Plans Bolster Buy Rating - TipRanks
Kyverna Therapeutics stock price target raised to $33 from $25 at Morgan Stanley - Investing.com
Can Kyverna Therapeutics Stock Surge Further? - StocksToTrade
Kyverna Therapeutics shares jump on positive Phase 2 SPS data | Tap to know more | Inshorts - Inshorts
Kyverna Therapeutics price target raised to $33 from $25 at Morgan Stanley - TipRanks
Kyverna Therapeutics: Promising Outlook with Breakthrough CAR-T Therapy in Autoimmune Diseases - TipRanks
Tesla, iRobot, ServiceNow, Radiopharm Theranostics, Kyverna Therapeutics: Stocks Making The Biggest Moves Today - Asianet Newsable
KYTX Stock Skyrockets: Investors Take Notice - timothysykes.com
Tesla, iRobot, ServiceNow, Radiopharm Theranostics, Kyverna Therapeutics: Stocks making the biggest moves today - MSN
Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome (KYTX) - Seeking Alpha
KYTX: miv-cel achieved robust, durable efficacy and safety in SPS, supporting first-in-class approval - TradingView — Track All Markets
Kyverna Therapeutics (NASDAQ:KYTX) Hits New 12-Month HighStill a Buy? - MarketBeat
Kyverna to take autoimmune CAR-T to FDA after success in stiff person syndrome trial - Endpoints News
'Unprecedented' data prime Kyverna for 1st autoimmune CAR-T drug - Fierce Biotech
Kyverna Therapeutics Sees Unusually High Options Volume (NASDAQ:KYTX) - MarketBeat
Kyverna shares spike as CAR-T hits endpoints in stiff person syndrome - FirstWord Pharma
Kyverna Therapeutics announces topline data from registrational KYSA-8 trial - TipRanks
Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease - BioPharma Dive
Why Is Kyverna Therapeutics Stock Skyrocketing Monday?Kyverna Therapeutics (NASDAQ:KYTX) - Benzinga
Kyverna rises on stiff person syndrome data - pharmaphorum
Kyverna Reports Positive Phase 2 Trial Results - TipRanks
Kyverna shares jump on strong results from SPS clinical trial - MSN
KYTX Stock Just Surged 11% Today – What Is The Connection With Stiff Person Syndrome? - Stocktwits
Kyverna Shares Surge on Strong Topline Results From Phase 2 SPS Trial - Tokenist
Kyverna Therapeutics stock soars after positive SPS trial data By Investing.com - Investing.com UK
Kyverna Therapeutics stock soars after positive SPS trial data - Investing.com
KYTX stock just surged 11% today – what is the connection with stiff person syndrome? - MSN
KYTX: Miv-cel achieved robust efficacy and safety in SPS, supporting a 2026 FDA submission - TradingView — Track All Markets
Kyverna Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Kyverna jumps after cell therapy meets main goal of mid-stage study - TradingView — Track All Markets
Kyverna's cell therapy meets main goal of mid-stage study - TradingView — Track All Markets
Kyverna Therapeutics shares surge 24% premarket after positive trial data - marketscreener.com
Kyverna Therapeutics Announces Positive Topline Data From Registrational Kysa-8 Trial Of Miv-Cel (Kyv-101) In Stiff Person Syndrome - TradingView — Track All Markets
Kyverna Therapeutics Announces Positive Topline Data from KYSA-8 Trial - TradingView — Track All Markets
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of ... - Bakersfield.com
Kyverna Therapeutics Announces Positive Topline Data from - GlobeNewswire
Kyverna Therapeutics Inc Stock Analysis and ForecastSector Rotation Strategies & Free Stock Chart Pattern Guides - earlytimes.in
2 'strong buy' biotech stocks with 208% to 329% upside potential - MSN
Kyverna to present topline results from Phase 2 trial in stiff person syndrome - Investing.com
Kyverna Therapeutics to Present Topline Results from Phase 2 KYSA-8 Clinical Trial for KYV-101 in Stiff Person Syndrome - Quiver Quantitative
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome - The Manila Times
Kyverna Therapeutics to Report Topline Results from - GlobeNewswire
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Palmetto Grain Brokerage - Palmetto Grain Brokerage
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential - Yahoo Finance
Momentum Shift: What is the fair value of Kyverna Therapeutics Inc stock now2025 Market Overview & Smart Swing Trading Alerts - moha.gov.vn
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Morgan Stanley maintains Kyverna Therapeutics (KYTX) overweight recommendation - MSN
Kyverna Therapeutics price target raised to $25 from $20 at Morgan Stanley - TipRanks
Why analysts remain bullish on Kyverna Therapeutics Inc. stockMarket Growth Report & Stepwise Entry/Exit Trade Alerts - Newser
Published on: 2025-12-04 05:07:23 - Newser
How institutional buying supports Kyverna Therapeutics Inc. stock2025 Market Outlook & Risk Managed Investment Strategies - Newser
0.36%
1.05%
자본화:
|
볼륨(24시간):